Video

Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

Leslie M. Randall, MD, MAS, ​professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massey Cancer Center, VCU Health, discusses the unmet need​s in platinum-resistant ovarian cancer.

 Limited treatment options are available for patients with platinum-resistant ovarian cancer, representing a clear unmet need, explains Randall.

 Although chemotherapy is the standard of care, the response rate is approximately 15% in this setting, says Randall.

As such, the FDA accelerated approval pathway, which offers a potential opportunity to fulfill these unmet needs, still stands in the United States, Randall concludes.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center